Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab

Gerd Horneff 1*, Ariane Klein 1, Jens Klotsche 2, Kirsten Minden 2, Hans-Iko Huppertz 3, Frank Weller-Heinemann 3, Jasmin Kuemmerle-Deschner 4, Johannes-Peter Haas 5 and Anton Hospach 6

Abstract

Background: Treatment response, remission rates and compliance in patients with polyarticular juvenile idiopathic arthritis (polyJIA) treated with adalimumab, etanercept, or tocilizumab were analyzed in clinical practice.

Methods: Data collected in the German BIKER registry were analyzed in patients with polyJIA who started treatment with approved biologics, adalimumab, etanercept or tocilizumab, from 2011 to 2015. Baseline patient characteristics, treatment response, safety and drug survival were compared.

Results: Two hundred thirty-six patient started adalimumab, 419 etanercept and 74 tocilizumab, with differences in baseline patient characteristics. Baseline Juvenile Disease Activity Score (JADAS)10 (mean ± SD) in the adalimumab/etanercept/tocilizumab cohorts was 12.1+/−7.6, 13.8 ± 7.1 and 15.1 ± 7.4, respectively (adalimumab vs etanercept, p = 0.01), and Childhood Health Assessment Questionnaire (CHAQ)-disability index scores was 0.43 ± 0.58, 0.59 ± 0.6 and 0.63 ± 0.55, respectively (adalimumab vs etanercept, p < 0.001). Uveitis history was more frequent in the adalimumab cohort (OR 5.73; p < 0.001). Balanced patients’ samples were obtained by a generalized propensity score to adjust for baseline differences. Pediatric ACR30/50/70/90 criterion improvement after 3 months treatment was achieved by 68%/60%/42%/24% in the etanercept cohort, 67%/59%/43%/27% in the adalimumab cohort and 61%/52%/35%/26% in the tocilizumab cohort. At 24 months, JADAS minimal disease activity was achieved in 52.4%/61.3%/52.4% and JADAS remission in 27.9%/34.8%/27.9% patients in the adalimumab/etanercept/tocilizumab cohorts, respectively. Etanercept was used in 95.5% of patients as a first biologic, adalimumab in 50.8% and tocilizumab in 20.2%. There were no important differences in efficacy between first-line and second-line use of biologics. In total 60.4%/49.4%/31.1% patients discontinued adalimumab/etanercept/tocilizumab, respectively (HR for adalimumab 1.67; p < 0.001; HR for tocilizumab 0.35; p = 0.001). Drug survival rates did not differ significantly in patients on biologic monotherapy compared with combination therapy with methotrexate. Over 4 years observation under etanercept/adalimumab/tocilizumab, 996/386/103 adverse events, and 148/119/26 serious adverse events, respectively, were reported.

(Continued on next page)
Background
Juvenile idiopathic arthritis (JIA) is a collective term for arthritides that are diagnosed before the age of 16 years. Diagnosis requires disease duration of at least 6 weeks and the exclusion of other causes of arthritis [1]. JIA is the most common chronic rheumatic inflammatory disease of childhood. If not successfully treated, it can lead to severe disability [2].

Pharmacologic treatment consists of nonsteroidal anti-rheumatic drugs, mainly for symptomatic relief, and disease-modifying antirheumatic drugs (DMARDs). Of the latter group, methotrexate (MTX) is the most common first-line DMARD and is a cornerstone drug in the treatment of patients with JIA. Its efficacy was first demonstrated two decades ago in a randomized controlled trial [3]. According to national and international guidelines and recommendations, patients with JIA who are refractory to MTX treatment are eligible for treatment with biologic agents [4, 5].

Etanercept, an anti-TNF-α receptor immunoglobulin Fc fragment fusion protein, was the first biologic agent approved by the US Food and Drug Administration for the treatment of polyarticular JIA (pJIA) in 1999 and by the European Medicines Evaluating Agency in 2000. Its efficacy and safety were demonstrated in a randomized controlled withdrawal trial and several long-term observational studies from national registries, including the German Biologics in Pediatric Rheumatology (BIKER) Registry [9, 15]. In 2008, adalimumab, a monoclonal anti-TNF-α antibody, was approved for the treatment of polyarticular JIA, as monotherapy or in combination with MTX, after its efficacy was established in a placebo-controlled withdrawal trial [10]. Adalimumab was preferred over etanercept for the treatment of uveitis for years until a recent randomized placebo controlled trial demonstrated its efficacy for treatment of uveitis [11]. Observational data on the use of adalimumab for JIA are more limited than those on the use of etanercept [12]. Tocilizumab, a monoclonal interleukin-6 receptor antibody, was first approved for systemic onset JIA in 2011 and was found to be effective in a randomized controlled withdrawal trial [13]. Since 2013, Tocilizumab has been the third first-line biologic agent approved for treatment of polyarticular JIA.

The efficacy of these three agents for the treatment of JIA is considered to be equivalent [14]. However, no head-to-head trials have been conducted to compare etanercept, adalimumab or tocilizumab. All three biologic agents are approved for treatment of polyarticular JIA in children older than 2 years who do not respond to MTX. Therefore, the initial decision of which biologic agent to use must be determined based on limited evidence. The aim of this analysis was to compare baseline characteristics, efficacy, tolerability and drug survival in patients with polyarticular JIA initiating adalimumab, etanercept or tocilizumab.

Methods
The German BIKER Registry was approved by the local ethics committee. Written consent was obtained and pseudonymized data were collected. This registry has been extensively described in previous reports [9, 15]. Patients in the German BIKER registry initiating treatment with adalimumab, etanercept or tocilizumab between 1 January 2011 and 31 December 2015 were included in the study. The study population was restricted to patients who were classified in the following JIA categories: rheumatoid factor-positive polyarthritis, rheumatoid factor-negative polyarthritis and extended oligoarthritis. Patients with other JIA categories (systemic onset JIA, persistent oligoarthritis, psoriatic arthritis (PsA), enthesitis-related arthritis (ERA) and unclassified JIA) were excluded because of differences in the approval of the three biologics studied and to homogenize the study population.

For the efficacy analyses, assessments were performed at baseline and at follow up after 3 and 6 months and every 6 months thereafter. Due to the character of the registry study, the number of patients observed decreased with treatment duration. For this reason, efficacy was analyzed until month 24. Juvenile Disease Activity Score (JADAS) scores and improvement in the Pediatric American College of Rheumatology Criteria (PedACR) were calculated as previously described in detail [16, 17]. The JADAS minimal disease activity (MDA) (defined as JADAS10 ≤ 3.8) and JADAS remission rates (defined as JADAS10 ≤ 1) according to the definition of Consolaro et al. [18] were calculated. The JADAS10 was chosen because all four domains,
number of active joints (truncated at 10), patient’s/parent’s global assessment of disease activity, physician’s global assessment of disease activity, and erythrocyte sedimentation rate, ranged from 0 to 10 points. Functional status was determined using the Childhood Health Assessment Questionnaire (CHAQ) disability index [19].

Safety was analyzed based on adverse event reporting. An adverse event was defined as any untoward medical occurrence in a subject administered a pharmaceutical product, even without a causal relationship with the treatment. Serious adverse events included death, a life-threatening event or an event leading to or prolonging hospitalization, persistent or significant disability/incapacity or an important medical event requiring medical or surgical intervention to prevent a serious outcome or congenital anomaly or birth defect. For this analysis, reasons for discontinuation were classified as inefficacy, intolerance, remission or other reasons.

Statistical analysis
The adalimumab, etanercept and tocilizumab cohorts differed in their clinical characteristics and treatment history at baseline. A generalized propensity score was estimated to obtain balanced samples of patients in respect to baseline characteristics. The likelihood of being allocated to a cohort was estimated by a multinomial logistic regression model, including the predictors, sex, age at JIA onset, JIA category, disease duration, JADAS10, concomitant MTX use and the number of previously used biologic agents. Balanced samples of patients were obtained using an inverse probability of treatment weight. Generalised estimation equations (GEE) were applied to the weighted sample of patients to analyze the drug adherence and treatment response. Drug survival was analyzed by Kaplan-Meier plots and Cox proportional hazard model.

Results
Study population
The German BIKER registry database of 3547 patients with JIA was used to identify eligible patients. Patients diagnosed with rheumatoid factor-positive polyarthritis, rheumatoid factor-negative polyarthritis or extended oligoarthritis, who had initiated treatment with a biologic agent from 1 January 2011 to 31 December 2015, were considered. Up to December 2015, 236 patients started on adalimumab, 419 started on etanercept and 74 started on tocilizumab.

Clinical characteristics at treatment initiation significantly differed between the three groups (Additional file 1: Table S1). The propensity-score-weighted analyses of baseline characteristics resulted in balanced samples as reported in Table 1 except for sex and uveitis. Female predominance was more pronounced in the etanercept and adalimumab cohorts than in the tocilizumab cohort (Table 1). Compared with the etanercept cohort, patients in the adalimumab or tocilizumab cohort were slightly older. The distribution of the three analyzed JIA categories was comparable among medications despite a lower rate of patients diagnosed with extended oligoarthritis in the tocilizumab cohort compared with the other two cohorts combined.

Etanercept was used as a first biologic agent in 583 patients (79.9%), adalimumab in 174 patients (23.9%) and tocilizumab in 17 patients (2.3%). Thus, etanercept was preferred as a first-line biologic agent. Only 17 patients (4.1%) received etanercept as a second-line biologic agent. In the adalimumab cohort, approximately half (46.6%) of the patients received adalimumab as the first biologic agent, while only 18.9% in the tocilizumab cohort received tocilizumab as the first biologic agent.

Compared with the etanercept cohort, the baseline JADAS10 and CHAQ-disability index were lower in the adalimumab cohort. Concomitant uveitis was present in 23 (5.5%) of the etanercept cohort, in 58 (25%) of the adalimumab cohort and in no patients in the tocilizumab cohort. Thus, uveitis demonstrated the highest frequency in patients treated with adalimumab (odds ratio 3.41 (95% CI 3.21; 4.45); p = 0.03).

At baseline, 302 patients (72%) in the etanercept cohort but only 127 (54%) in the adalimumab and 34 (46%) in the tocilizumab cohort received concomitant therapy with MTX. The differences described were not statistically significant after weighting the analyses with the propensity score weight (Table 1).

Treatment response
The mean treatment duration was comparable among all cohorts (1.25 ± 1.05 years in the etanercept cohort, 1.0 ± 0.86 in the adalimumab cohort and 0.98 ± 0.59 in the tocilizumab cohort). Improvement according to PedACR30/50/70/90 criteria was reached after 3 months by 68%/60%/42 %/24 % in the etanercept cohort, 67%/59%/43%/27% in the adalimumab cohort and 61%/52%/35%/26% in the tocilizumab cohort, respectively. The response rates further increased or were stable with continuing treatment (Fig. 1). There were no statistically significant differences between the three groups in the PedACR response rates. PedACR response rates to etanercept/adalimumab/tocilizumab, either as first-line or second-line biologic agents, were comparable (Additional file 2: Figure S1).

At baseline, the mean observed JADAS10 was highest in the tocilizumab (15.1 ± 7.4) and etanercept (13.8 ± 7.1) cohorts (p > 0.05) and significantly lower in the adalimumab cohort (12.1 ± 7.6; p = 0.003 compared to etanercept; p = 0.011 compared to tocilizumab). The significant differences in baseline JADAS10 disappeared after weighting the analyses (Table 1, Fig. 2).
A significant decrease in the adjusted JADAS10 was observed in all three cohorts (Fig. 2). From baseline to the last observation on treatment, the JADAS10 decreased by 8.6 (95% CI 7.6; 9.5) points in the etanercept cohort, by 7.3 (95% CI 5.8; 8.6) in the adalimumab cohort and by 5.1 (95% CI 1.5; 8.4) in the tocilizumab cohort. The decrease in JADAS10 did not significantly differ among the three cohorts. The mean decrease in JADAS10 was \(-7.7\) (95% CI \(-8.47; -6.99\)) in patients with rheumatoid factor-negative polyarthritis or extended oligoarthritis.

### Table 1

|                | Etanercept cohort | Adalimumab cohort | Tocilizumab cohort | Etanercept versus adalimumab\(^a\) | Tocilizumab versus etanercept\(^a\) | Tocilizumab versus adalimumab\(^a\) |
|----------------|-------------------|-------------------|-------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| Female, n (%)  | 332 (79.2%)       | 192 (81.4%)       | 51 (68.8%)        | 0.96 (0.57; 1.62); 0.88            | 0.63 (0.45; 0.89); 0.03            | 0.58 (0.48; 0.98); 0.04            |
| Age at baseline, years, mean ± SD | 10.5 ± 4.4 | 11.8 ± 4.0 | 12.9 ± 3.6 | 0.63 (−0.31; 1.57); 0.19 | 1.65 (−0.67; 3.96); 0.16 | 1.02 (−1.31; 3.34); 0.39 |
| Median (IQR)   | 11.1 (7.1–13.9)   | 12.7 (8.7–15.0)   | 13.5 (11.2–15.9)  |                                    |                                   |                                    |
| Disease duration at treatment start, mean ± SD | 3.6 ± 3.3 | 5.8 ± 4.0 | 6.1 ± 3.5 | 0.40 (−0.17; 0.98); 0.17 | 1.13 (−0.05; 2.02); 0.07 | 0.73 (−0.21; 1.66); 0.13 |
| Median (IQR)   | 2.6 (1.1–5.1)     | 4.9 (2.4–8.4)     | 5.8 (2.9–8.8)     |                                    |                                   |                                    |
| JIA category n (%) |                      |                    |                   |                                    |                                   |                                    |
| RF+ PA         | 37 (8.8%)         | 23 (9.7%)         | 9 (12.2%)         | 1.45 (0.74; 2.83); 0.28            | 0.95 (0.60; 1.49); 0.81            | 2.18 (0.48; 9.85); 0.31            |
| RF- PA         | 224 (53.5%)       | 128 (54.2%)       | 47 (63.5%)        | (ref)                             | (ref)                             | (ref)                             |
| ExOA           | 158 (37.7%)       | 85 (36.0%)        | 18 (24.3%)        | 3.17 (0.74; 13.60); 0.12           | 0.71 (0.22; 2.27); 0.57           | 0.75 (0.24; 2.41); 0.63           |
| First biologic used | 400 (95.5%) | 110 (46.6%) | 14 (18.9%) | 0.54 (0.28; 1.03); 0.06 | 0.44 (0.16; 1.18); 0.10 | 0.81 (0.34; 1.96); 0.65 |
| Co-med corticosteroids, n (%) | 134 (32.0) | 60 (25.4) | 26 (35.1) | 1.38 (0.96; 1.97) | 1.15 (0.69; 1.94) | 1.59 (0.99; 2.78) |
| Co-med MTX, n (%) | 302 (72.1) | 127 (53.8) | 34 (45.9) | 1.20 (0.76; 1.88); 0.44 | 0.76 (0.28; 2.06); 0.59 | 0.64 (0.24; 1.70); 0.37 |
| JADAS10 (0–40), mean ± SD | 13.8 ± 7.1 | 12.1 ± 7.6 | 15.1 ± 7.4 | −0.41 (−2.30; 1.48); 0.67 | −0.53 (−4.22; 3.17); 0.78 | −0.12 (−3.84; 3.60); 0.95 |
| Median (IQR)   | 13.6 (8.8–19.0)   | 11.7 (6.1–17.5)   | 14.8 (9.2–20.1)   |                                    |                                   |                                    |
| CHAQ-DI (0–3), mean ± SD | 0.59 ± 0.60 | 0.43 ± 0.58 | 0.63 ± 0.55 | −0.04 (−0.19; 0.12); 0.64 | −0.10 (−0.30; 0.11); 0.35 | −0.06 (−0.29; 0.17); 0.60 |
| Median (IQR)   | 0.38 (0.13–0.88)  | 0.13 (0–0.623)    | 0.63 (0.19–1.0)   |                                    |                                   |                                    |
| Uveitis before start of biologic | 23 (5.5%) | 59 (25%) | 0 | 3.41 (3.21; 4.45); 0.03 | - | - |

\(^a\)Analyses weighted by an inverse probability of treatment estimated by a generalized propensity score. \(\beta\) regression coefficient for continuous variables, CI confidence interval, OR odds ratio for categorical variable, (ref) reference group, JIA juvenile idiopathic arthritis, RF rheumatoid factor, PA polyarthritis, ExOA extended oligoarthritis, JADAS Juvenile Disease Activity Score, CHAQ-DI Childhood Health Assessment Questionnaire disability index.
oligoarthritis, and −9.4 (95% CI −12.13; −6.63) for rheumatoid factor-positive polyarthritis. The difference between the JIA categories in the JADAS10 response was not statistically significant (delta = 1.51; 95% CI −0.54; 3.56; p = 0.149).

JADAS remission and JADAS-MDA were used as further treatment response indicators. In the etanercept, adalimumab and tocilizumab cohorts, 131 patients (34.8%), 71 patients (27.9%) and 16 patients (23.5%), respectively, achieved JADAS remission (defined as JADAS10 ≤ 1.0) at the last observation. The three cohorts did not significantly differ in JADAS remission at the last observation adjusting for baseline differences between the three cohorts. The rates of achieving JADAS-MDA were comparable among all three cohorts (Fig. 3): 231 patients (61.3%), 133 patients (52.4%) and 32 patients (47.1%) in the etanercept, adalimumab and tocilizumab cohorts, respectively, achieved JADAS-MDA (defined as JADAS10 ≤ 3.8) at the last observation.

Patients who were first exposed to biologic agents were compared to those who switched from a first to a second biologic agent. The mean (± SD) JADAS10 in the cohort previously exposed to a biologic agent (14.8 ± 7.3) was not significantly lower than that in the biologic-agent-naïve cohort (16.5 ± 7.2). The decline in JADAS10 at 3, 6, 12, 18 and 24 months, respectively, was 3.9 ± 3.3, 6.2 ± 7.4, 9.6 ± 7.7, 6.6 ± 5.9 and 2.9 ± 2.4 in the biologic-naïve group, and 8.9 ± 6.5, 7.6 ± 8.2, 4.6 ± 5.6, 3.2 ± 4.5 and 7.7 ± 8.8 in the cohort switching from a first to a second biologic. The decline in JADAS and the rates of achieving JADAS remission and JADAS-MDA were again comparable among the cohorts.

Functional disability was analyzed using the CHAQ-DI. The observed baseline CHAQ-DI was highest in the...
tocilizumab cohort (0.63 ± 0.55), followed by the etanercept cohort (0.59 ± 0.60) and the adalimumab cohort (0.43 ± 0.58). However, the baseline CHAQ-DI did not differ among the three cohorts in the propensity-score-weighted analyses. Reductions in CHAQ-DI from baseline to the last observation in the tocilizumab, etanercept and adalimumab cohorts were (−0.31 ± 0.46), (−0.22 ± 0.54) and (−0.12 ± 0.47), respectively. Reduction in the CHAQ-DI was significantly greater in the etanercept cohort than in the adalimumab cohort (p = 0.032). There was no significant difference in the reduction in the CHAQ-DI between the tocilizumab and the etanercept cohort (p = 0.261). However, the residual CHAQ-DI at the last observation was comparable among all three cohorts (etanercept 0.31 ± 0.44, adalimumab 0.29 ± 0.48 and tocilizumab 0.36 ± 0.46).

Drug adherence and discontinuations

Drugs were discontinued by 142 patients (60.2%) in the adalimumab cohort versus 207 patients (49.4%) in the etanercept cohort and 23 patients (31.1%) in the tocilizumab cohort. The median drug survival before discontinuation due to inefficacy or intolerance was 2.85 years for adalimumab and 4.29 years for etanercept; this was not calculated for tocilizumab because more than 50% of the patients were still receiving treatment (Fig. 4). Survival analyses using Cox proportional hazard regression revealed significant differences between adalimumab and etanercept survival (hazard ratio 2.82, 95% CI 1.55; 5.14; p < 0.001), between adalimumab and tocilizumab survival (hazard ratio 4.71, 95% CI 2.58; 8.61; p < 0.001), and between etanercept and tocilizumab survival (hazard ratio 2.82, 95% CI 1.55; 5.14; p = 0.001).

Drug survival with adalimumab (hazard ratio 1.36, 95% CI 1.03; 1.78; p = 0.029) was improved but was significantly lower compared to etanercept when restricting the analyses to patients who took etanercept and adalimumab as their first biologic agents. Interestingly, the survival rates of patients on monotherapy with a biologic agent compared with combination therapy with MTX were not significantly different (p = 0.836) regardless of whether they were calculated separately in the etanercept, adalimumab or tocilizumab cohort (data not shown) or for the combined analysis (Additional file 3: Figure S2).

Patients with rheumatoid factor-negative polyarthritis or extended oligoarthritis had a comparable drug survival to patients with rheumatoid factor-positive polyarthritis (hazard ratio = 0.995, 95% CI 0.67; 1.47; p = 0.98). Drug survival also did not statistically significantly differ between the JIA categories in the adalimumab (hazard ratio = 1.15, 95% CI 0.62; 2.12; p = 0.653) and etanercept (hazard ratio = 0.83, 95% CI 0.48; 1.43; p = 0.502) cohorts.

The reasons for discontinuation are provided in Table 2. The most common reason for discontinuation was poor efficacy or unsatisfactory response. Significantly more patients discontinued adalimumab (odds ratio 4.89, 95% CI 1.65; 14.48; p = 0.004) for reasons of inefficacy (n = 52 (22%)) than tocilizumab (n = 9 (12.2%)). Remission was the second leading reason for discontinuation of a biologic
|                           | Etanercept cohort | Adalimumab cohort | Tocilizumab cohort | Adalimumab versus etanercept<sup>a</sup> | Tocilizumab versus etanercept<sup>a</sup> | Tocilizumab versus adalimumab<sup>b</sup> |
|---------------------------|-------------------|-------------------|-------------------|------------------------------------------|------------------------------------------|------------------------------------------|
| Discontinuations, n (%)   | 207 (49.4)        | 142 (60.4)        | 23 (31.1)         | 1.57 (1.03; 2.41); 0.037                 | 0.20 (0.09; 0.45); <0.001               | 0.13 (0.06; 0.29); <0.001               |
| Inefficacy, n (%)         | 50 (11.9)         | 52 (22.0)         | 9 (12.2)          | 1.65 (0.88; 3.08); 0.118                 | 0.34 (0.11; 1.00); 0.050               | 0.20 (0.07; 0.60); 0.004               |
| Remission, n (%)          | 54 (12.9)         | 22 (9.3)          | 2 (2.7)           | 0.78 (0.43; 1.40); 0.404                 | 0.12 (0.02; 0.79); 0.027               | 0.16 (0.02; 1.05); 0.056               |
| Intolerance, n (%)        | 15 (3.6)          | 15 (6.4)          | 2 (2.7)           | 2.28 (1.03; 5.04); 0.042                 | 0.84 (0.18; 4.01); 0.826               | 0.37 (0.08; 1.79); 0.216               |
| Details                   |                   |                   |                   |                                          |                                          |                                          |
|                          | Hypersensitivity 5 | Infections (4)<sup>b</sup> | Impetigo (1)      |                                          |                                          |                                          |
|                          | Lymphoma (1)      |                   |                  |                                          |                                          |                                          |
|                          | Vasculitis (1)    |                   |                  |                                          |                                          |                                          |
|                          |                   |                   |                  |                                          |                                          |                                          |
|                          |                   |                   |                  |                                          |                                          |                                          |
| Others*, n (%)            | 88 (16.0)         | 53 (22.4)         | 10 (13.4)         | 1.21 (0.74; 1.96); 0.443                 | 0.27 (0.10; 0.72); 0.009               | 0.22 (0.08; 0.60); 0.003               |

<sup>a</sup>Analyses weighted by an inverse probability of treatment estimated by a generalized propensity score. <sup>b</sup>Infections included pneumonia and soft tissue infections; Neuropsychiatric included headache, nausea, aggressiveness, anxiety, and vertigo. beta regression coefficient for continuous variables, CI confidence interval, OR odds ratio for categorical variable.
agent. Significantly more patients discontinued etanercept due to remission (n = 54 (12.9%); odds ratio 8.24 (95% CI 1.27; 53.53); p = 0.027) than tocilizumab (n = 2 (2.7%)). In general, few patients discontinued due to intolerance (etanercept, n = 15 (3.6%); adalimumab, n = 15 (6.4%); tocilizumab, n = 2 (2.7%)). Patients treated with adalimumab had a higher odds for discontinuation due to intolerance (odds ratio 2.28, 95% CI 1.03; 5.04; p = 0.042) than etanercept. The reasons for discontinuation included infections, hypersensitivity, neuropsychiatric events, vasculitis, lymphoma (one patient) and others (Table 2).

Safety
A total of 1484 adverse events (AE) were reported, of which there were 996 in patients receiving etanercept, 386 in patients receiving adalimumab and 102 in patients receiving tocilizumab. Of the adverse events, 148 were classified as serious adverse events (SAE), comprising 119 patients on etanercept, 26 patients on adalimumab and 3 patients on tocilizumab. Thus, the rates of AE and SAE were significantly higher with etanercept than with the other biologic agents (Table 3).

The AE and SAE were classified as adverse events of special interest (AESI) if they represented new onset or aggravation of uveitis (n = 88), serious or medically important infections (n = 66), neutropenia (n = 26), hepatitis/elevated transaminases (n = 19), chronic inflammatory bowel disease (CED, n = 14), intolerance (n = 7), new onset of autoimmunity (n = 6), pregnancy (n = 6), bleeding disorders (n = 5), hyperlipidemia (n = 4), stroke (n = 2), malignancy (n = 1), thrombosis (n = 1), or demyelination (n = 1). There were no deaths.

Serious or medically important infections observed in the etanercept cohort included pneumonia (n = 9), primary

---

**Table 3 Safety**

|                  | ADA | ETA | TOC | ETA vs ADA | ADA vs TOC | ETA vs TOC |
|------------------|-----|-----|-----|------------|------------|------------|
| Patients, n      | 236 | 419 | 74  |            |            |            |
| Patient years, n | 236.4| 524.096| 72,473,648| 1.16 (1.03–1.31) | ns          | RR 1.35 (1.1–1.66) |
| Exposure, years mean ± SD | 1.00 ± 0.86 | 1.25 ± 1.05 | 0.98 ± 0.60 | p = 0.011 | p = 0.004 |
| Adverse events, n/patient | 386/1.63 | 996/2.37 | 102/1.38 |            |            |            |
| Rate/100 PY (95% CI) | 163.3 (148.8; 180.4) | 190.0 (178.6; 202.2) | 140.7 (113.5; 167.4) | RR 2.06 (1.35–3.16) | ns          | RR 5.48 (1.74–17.25) |
| Serious adverse events, n/patient | 26/0.11 | 119/0.28 | 3/0.04 | p = 0.0008 | p = 0.004 |
| Rate/100 PY (95% CI) | 11.0 (7.5; 16.2) | 22.07 (19.0; 27.2) | 4.1 (1.3; 12.8) |            |            |            |
| Autoimmunopathy, n/patient | 3/0.12 | 2/0.04 | 1/0.014 |            |            |            |
| Rate/100 PY (95% CI) | 1.27 (0.41; 3.39) | 0.38 (0.09; 1.53) | 1.38 (0.19; 9.59) | ns          | ns          | ns          |
| Bleeding disorder, n/patient | 2/0.008 | 3/0.007 | 0 |            |            |            |
| Rate/100 PY (95% CI) | 0.85 (0.21; 3.38) | 0.57 (0.18; 1.17) | ns          | ns          | ns          | ns          |
| CED, n/patient | 1/0.04 | 13/0.031 | 0 | p = 0.09 |            | ns          |
| Rate/100 PY (95% CI) | 0.42 (0.06; 3.0) | 2.48 (1.44; 4.27) | RR 5.86 (0.77–44.83) | ns          | ns          |
| Demyelisation | 0 | 1/0.002 | 0 |            |            |            |
| Rate/100 PY (95% CI) | 0.19 (0.03-1.35) | ns          | ns          | ns          | ns          |
| Hepatitis | 6/0.025 | 10/0.024 | 3/0.041 |            |            | ns          |
| Rate/100 PY (95% CI) | 2.54 (1.14; 5.65) | 1.91 (1.03; 3.55) | 4.14 (1.31; 12.57) | ns          | ns          | ns          |
| Hyperlipidemia | 0 | 3/0.007 | 1/0.014 |            |            | ns          |
| Rate/100 PY (95% CI) | 0.57 (0.18; 1.17) | 1.38 (0.19; 9.59) | ns          | ns          | ns          |
| Infection, serious or medically important; n/patient | 13/0.055 | 50/0.119 | 3/0.041 | p = 0.076 | ns          | ns          |
| Rate/100 PY (95% CI) | 5.5 (3.19; 9.47) | 9.54 (7.23; 12.59) | 4.14 (1.31; 12.57) | RR 1.73 (0.94–3.19) | ns          | ns          |
| Intolerance, n/patient | 2/0.008 | 3/0.007 | 2/0.027 |            |            | ns          |
| Rate/100 PY (95% CI) | 0.85 (0.21; 3.38) | 0.57 (0.18; 1.17) | 2.76 (0.68; 10.81) | ns          | ns          | ns          |
| Malignancy, n/patient | 0 | 1/0.002 | 0 |            |            | ns          |
| Rate/100 PY (95% CI) | 0.19 (0.03; 1.35) | ns          | ns          | ns          | ns          |

ADA adalimumab, ETA etanercept, TOC tocilizumab, PY person years, ns not significant, RR relative risk
varicella \((n = 7, \text{none were vaccinated})\), zoster \((n = 14)\), pyelonephritis \((n = 5)\), peritonitis \((n = 2)\), appendicitis \((n = 2)\) and cellulitis \((n = 2)\). The events observed with adalimumab were pneumonia \((n = 2)\), primary varicella \((n = 4, \text{none were vaccinated})\), zoster \((n = 3)\), osteomyelitis \((n = 1)\), septic arthritis \([1]\) appendicitis \((n = 1)\) and influenza \((n = 1)\). For tocilizumab, one case each of pneumonia, appendicitis and influenza was reported. No cases of tuberculosis occurred, and apart from herpes zoster, no opportunistic infections were observed.

Some differences in the occurrence of specific AESI were noted among the three treatment cohorts. Neutropenia and serious or medically important infections occurred with significantly greater frequency in the etanercept cohort compared with the adalimumab cohort. Aggravation of uveitis occurred more frequently in the adalimumab cohort than in the tocilizumab cohort, whereas neutropenia occurred significantly less frequently. Compared with the tocilizumab cohort, aggravation and new onset of uveitis occurred more frequently in the etanercept cohort.

Notably, serious or medically important infections and events of chronic inflammatory bowel disease occurred more frequently in the etanercept cohort than in the adalimumab cohort. However, this difference was not significant \((p < 0.05, \text{Table 3})\).

**Discussion**

To our knowledge, this is the first study to directly compare adalimumab, etanercept, and tocilizumab as therapy for polyarticular JIA. Data analysis was restricted to patients initiating treatment after 2011, when tocilizumab became available for the treatment of JIA. The patient population was further restricted to patients with rheumatoid factor-positive or rheumatoid factor-negative polyarthritis and extended oligoarthritis. Patients with systemic JIA (sJIA), enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) were excluded to acquire a more homogenous patient population and to avoid the effect of differences in approval among the respective drugs; etanercept is approved for ERA and PsA, adalimumab for ERA and tocilizumab for sJIA.

Etanercept was approved for polyarticular JIA in 2000, and adalimumab was approved in 2008. Therefore, considerably more experience has been gained with etanercept than with adalimumab or tocilizumab. Accordingly, etanercept was used much more frequently than either adalimumab or tocilizumab. In the Dutch ABC registry, etanercept was also the most frequently prescribed biologic agent for non-systemic JIA \([20]\). In that study, greater drug experience was the most important factor driving the decision to use etanercept rather than adalimumab. Adalimumab was favored by Dutch pediatric rheumatologists for patients who had preceding uveitis.

Similar findings were obtained in the current BIKER population.

For German pediatric rheumatologists, we may speculate that the number of patients starting on etanercept as their first biologic agent is higher because there is prolonged experience with etanercept compared to the other biologic agents. Adalimumab was predominantly chosen as the first biologic agent in patients with concomitant uveitis. Finally, the relative rarity of using tocilizumab can either be attributed to the fact that first, it is the biologic agent with the least experience of use and second, that currently only the intravenous infusion is approved, which means it can only be used in centers with an infusion facility. The decision as to which biologic agent is used is not influenced by a protocol, algorithm, national recommendation or guideline, or by the registry itself. Adalimumab was used more frequently than etanercept as a second-line biologic agent but had comparable efficacy in both second-line and first-line users \([12]\).

There were few other differences among the studied cohorts. Patients in the adalimumab or tocilizumab cohorts were older than those in the etanercept cohort, and there were fewer patients with extended oligoarthritis in the tocilizumab cohort. A striking difference was observed in use of concomitant MTX, which was much more common in the etanercept cohort, followed by the adalimumab cohort. Fewer than 50% of the patients in the tocilizumab cohort received concomitant MTX therapy. This observation was surprising because etanercept is approved only for monotherapy, whereas both of the other biologic agents are also approved for combination therapy.

Despite these differences, PedACR treatment response rates were comparable for all three biologic agents. The majority of patients demonstrated marked improvement after 3 months of treatment. The response rates thereafter remained stable or increased further. No apparent differences among the three treatment cohorts were noted, in accordance with the response rates observed in open-label phases of the pivotal randomized controlled withdrawal studies of each of the drugs \([6, 13, 21]\). However, in the most recent clinical trial investigating etanercept, patients with extended oligoarticular JIA experienced a much higher rate of clinical improvement \([9]\).

There was a small but significant difference in reported absolute disease activity at baseline, as measured by the JADAS10, which was highest in the tocilizumab cohort and lowest in the adalimumab cohort. This difference was balanced by the inverse probability of treatment allocation estimated by a generalized propensity score. The JADAS score fell significantly in all cohorts after treatment. The residual JADAS at the last observation (mean observation time in all cohorts of approximately 1 year) was highest in
the etanercept cohort. The greatest adjusted mean reduc-
tion in the JADAS was observed in the etanercept cohort; in
contrast, the greatest observed mean reduction was in the
tocilizumab cohort.

As tocilizumab may have had a higher influence on
the acute phase response via its inhibitory capability on
the IL-6 axis, the JADAS10 and the clinical JADAS
(cJADAS), which considers only three clinical parameters
were compared. Interestingly, at baseline 144 of 407
patients (35.4%) in the etanercept cohort and 26 of 74
patients (35.1%) in the tocilizumab cohort had higher
classic JADAS than cJADAS. Upon treatment (month 3
to 24), 91 of 856 patients (10.6%) in the etanercept co-
hort and 22 of 187 patients (12.4%) from the tocilizumab
cohort had higher classic JADAS than cJADAS. Thus,
both at baseline and after treatment the results were
very much comparable, and direct inhibition of IL-6
seems not to influence the laboratory parameters of the
JADAS10 more than TNF inhibition. As we used defini-
tions for MDA and remission based on the complete
JADAS, the original JADAS10 was preferred over the
cJADAS, which considers only three clinical parameters.
Comparable numbers of patients achieved JADAS remis-
sion and JADAS minimal disease activity in a large data-
base study [16, 18]. No differences were identified
among the cohorts in terms of either speed to remis-
sion/MDA or absolute remission/MDA rates.

Interestingly, the drug survival rates for the three bio-
ologic agents were different in this study. Whereas etan-
ercept and tocilizumab showed comparable drug survival,
significantly more patients discontinued adalimumab.
The main reason for adalimumab discontinuation was
lack of therapeutic response or inefficacy, which differed
significantly compared with the discontinuation fre-
cuency with etanercept due to inefficacy/lack of ther-
apeutic effect. This could have been influenced by the
higher proportion of patients on MTX in the etanercept
cohort. It is possible that Adalimumab in monotherapy
could lead to more immunogenicity and secondary loss
of efficacy.

Remission was the second leading reason for drug dis-
continuation. Significantly fewer patients discontinued
tocilizumab than etanercept for reasons of remission.
This finding is remarkable because the rates of JADAS
remission were not different. The mean/median duration
of treatment with both etanercept and tocilizumab were
comparable. There were also no differences in the num-
ber of patients on prolonged treatment: a quarter of the
patients had been treated with etanercept for more than
1.7 years, which was comparable to more than 1.5 years
in a quarter of the patients using tocilizumab. It is likely
that tocilizumab adherence was affected by its more fre-
cuency use as a second-line biologic agent compared with
etanercept and thus an earlier biologic treatment had
failed. It can be speculated that in this situation, success-
ful drug treatment likely will not be discontinued.

Very few patients discontinued their biologic agent due
to intolerance, which suggests that they are not only very
effective but also very well-tolerated. The pattern of AE
observed in this study of patients with pJIA is consistent
with the known safety profile of adalimumab, etanercept
and tocilizumab [6, 10, 13]. Interestingly, there were no
cases of tuberculosis. Apart from herpes zoster, which has
been regarded as an opportunistic infection by some
authors, no other opportunistic infections were reported.
Furthermore, only one case of malignancy was reported,
in which an Epstein-Barr virus (EBV)-associated lymph-
oma developed in a child who had been treated with
MTX and etanercept. This observation is preliminary due
to the short observation period of this analysis to compare
biologic agents used contemporaneously, thus restricting
the analysis to patients treated after 2011. Notably, a
significant number of malignancies have been observed in
the BIKER registry since 2001 [22, 23].

The observed discontinuation rate was comparable to
that reported in an Italian cohort, in which 165 of 301
patients with various categories of JIA discontinued
biologic treatment [24]. The majority (135 patients) dis-
continued for reasons of treatment failure, including a
lack or loss of efficacy, and AE. Most patients discon-
tinued due to intolerance (34.6%), which was very different
compared with our cohort. This discrepancy can be
explained, in part, by the frequent use of infliximab in
the Italian cohort. Among this cohort, 39% of patients
discontinued biologic treatment due to adverse events.
Because infliximab is not approved for JIA in Germany,
 it cannot by studied systematically in BIKER.

In the present analysis, the overall safety of the biologic
agents was acceptable. The rate of serious or medically
important infections (4.1–9.5/100 patient-years) was com-
parable to that observed in other registry cohorts. In a
British cohort, medically important infections occurred
more frequently among users of TNF inhibitors than in a
non-biologic control cohort, but the rate of serious infec-
tions was not significantly different [25]. Interestingly,
new onset Crohn’s disease or ulcerative colitis mostly occurred
in the etanercept cohort, which is consistent with previous
findings [26]. Etanercept has been shown to lack efficacy
toward CED [27]. However, the rate of uveitis was highest
in the adalimumab cohort, which could be attributed to a
selection bias, as described previously [28]. Patients with
uveitis as a comorbidity had a four times higher chance of
receiving adalimumab rather than etanercept [28]. Other
AESI were reported infrequently. It is interesting to note
that the rates of reported neutropenia, hyperlipidemia or
elevated liver enzymes were not higher in the tocilizumab
cohort, as might be expected based on analyses conducted
in adult patients with rheumatoid arthritis [27].
The results from randomized controlled trials (RCT) cannot easily be extrapolated to routine care. Several specific features of the RCT must be considered. The inclusion and exclusion criteria may be responsible for a more homogenous study population; for example, comorbidities and concomitant drugs are usually exclusion criteria. Clinical control is tighter, prescribing practices are more stringent in a trial over time, and drug adherence may be influenced by the desire to retain a patient in the study. Thus, the RCT population may not reflect routine clinical care. By comparison, registry analyses reflect routine care and may, in part, be superior to RCTs despite having other limitations.

Observational studies of cohorts of unselected patients receiving routine care may allow better comparisons of the drugs used, although the lack of randomization must be considered when interpreting the results. In a smaller Dutch observational study of 214 patients with JIA [29], the use of etanercept and adalimumab was evaluated in routine care; however, neither the efficacy nor the survival rates were compared.

Our results reflect clinical practice and do not include the very early introduction of biologic agents, which has been evaluated in the TREAT and ACUTE-JIA studies [30, 31]. Furthermore, the observations obtained from a registry are not a substitute for clinical trials. Comparative head-to-head studies with biologic agents in juvenile idiopathic arthritis as performed in adult patients with rheumatoid arthritis would be an ideal approach, but the lower prevalence of JIA may render this an unrealistic target.

Conclusions
So far, in clinical practice etanercept remains the most frequently used first-line biologic agent for the treatment of polyarticular JIA. The three biologic agents adalimumab, etanercept and tocilizumab had comparable efficacy. Overall, tolerance was acceptable. Interestingly, compliance was highest with tocilizumab and lowest with adalimumab. This study provides the first indication for the comparison of different biologic agents in polyarticular JIA based on observational study data, with all their weaknesses, and demonstrates the need for well-controlled head-to-head studies for confirmation.

Additional files

Additional file 1: Table S1. Patient characteristics (unweighted as reported in BIKER). (DOCX 17 kb)

Additional file 2: Figure S1. Pediatric ACR30/50/70/90 improvement in patients receiving etanercept, adalimumab or tocilizumab as a first-line or second-line biologic agent. (PPT 172 kb)

Additional file 3: Figure S2. Drug survival during treatment with etanercept, adalimumab or tocilizumab (combined cohorts) depending on the concomitant use of methotrexate, weighted Kaplan-Meier analyses weighted by an inverse probability of treatment estimated by a generalized propensity score. No significant differences were found between the two groups. (PPT 74 kb)

Abbreviations
AE: adverse event; AESI: adverse events of special interest; BIKER: Biologics in Pediatric Rheumatology Registry; CHAQ: Childhood Health Assessment Questionnaire; DMARD: disease-modifying antirheumatic drug; ERA: enthesitis-related arthritis; GEE: generalised estimation equations; HR: hazard ratio; IL: interleukin; JADAS: Juvenile Disease Activity Score; JIA: juvenile idiopathic arthritis; MADA: minimal disease activity; MTX: methotrexate; PedACR: Pediatric ACR criteria; PsA: psoriatic arthritis; RCT: randomized controlled trials; SAE: serious adverse event; SD: standard deviation; sJIA: systemic juvenile idiopathic arthritis; TNF: tumor necrosis factor

Acknowledgements
The BIKER study group included the pediatric rheumatology departments at the following universities and hospitals in Austria and Germany: Aachen, Berlin-Charme, Berlin-Buch, Bremen, Celle, Duesseldorf, Hamburg, Innsbruck, Neunkirchen, Saarbruecken, Stuttgart, Tuebingen, Ulm and Vienna. This study would not have been possible without the collaboration of numerous German and Austrian pediatric rheumatologists, patients and their parents. Collaborators: Angelika Thon, Gerd Ganser, Markus Hufnagel, Christian Hedrich, Andreas Urban, Ralf Trauzeddel, Daniel Windschall, Frank Dressler, Prasad Oommen, Rolf Kuester, Doris Meyer, Gundula Böschow, Michael Rühlmann, Dirk Fall, Retschel, Beno-Ulrich, Keck, Michael Borte, Thomas Berger, Maria Haller, Bettina Rogalski, Wolfgang Emminger, Ina Feddersen, Michaela Sailer-Hoeck, Catarina Schuetz, Hermann Girschick, Thilo Schmalbach, Sonja Mrusek.

Funding
The study sponsor according to law is GH. The BIKER registry is supported by an unrestricted grant from Pfizer, Germany, Abbvie, Germany and Roche, Germany. The companies had no influence on study design or on the collection, analysis, or interpretation of the data, the writing of the manuscript or the decision to submit the manuscript for publication. Publication of this article was not contingent upon approval by the study sponsors, the German Registry.

Availability of data and materials
Not applicable.

Authors’ contributions
GH conceived the study, contributed to study design, performed data analysis and interpretation and drafted the paper. AK performed data analysis and interpretation and drafted the paper. JK performed the statistical analysis. KM was involved in the conception of the study, contributed to study design and performed data analysis and interpretation. HIH, FWH, JKD, GH conceived the study, contributed to study design, performed data analysis and interpretation and drafted the paper. KM was involved in the conception of the study and helped to draft the manuscript. All authors read and approved the final manuscript.

Competing interests
Gerd Horneff has received research funds, advisory board membership and honorary fees from Abbvie, Pfizer and Roche. Kirsten Minden has received research grants from Abbvie, Pfizer and Roche and honorary fees from Abbvie, Pfizer, Genzyme and Pharm-AIlergen. Toni Hospach has received advisory board membership and honoraria from Pfizer, Abbvie and Roche.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The study was conducted in accordance with the protocol, ICH GCP, FDA regulations governing clinical study conduct, ethical principles that have their origin in the Declaration of Helsinki, 1996 revision and 2000 revision
with subsequent clarifications, and all applicable local regulations. Before the study was initiated, the study protocol, the informed consent form and subject information were submitted to the responsible independent ethics committee of the Azerettkommer nordhein, Duesseldorf, Germany for review. Parents/legal guardian signed the informed consent form before any study-related procedures occurred.

Author details
1Department of Pediatrics, Centre of General Pediatrics and Neonatology, Asklepios Clinic Sant Augustin, 53757 Sant Augustin, Germany. 2German Rheumatism Research Centre Berlin, and Children’s University Hospital Charité, Berlin, Germany. 3Prof Hess Children’s Hospital, Bremen, Germany. 4Department of Pediatrics, University of Tuebingen, 72076 Tuebingen, Germany. 5German Centre for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany. 6Department of Pediatrics, Section of Rheumatology, Olghospital, Klinikum, Stuttgart, Germany.

Received: 2 June 2016 Accepted: 4 November 2016
Published online: 24 November 2016

References
1. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldberg J, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–2.
2. Danner S, Sordet C, Terzic J, Donato L, Velten M, Fischbach M, et al. Epidemiology of juvenile idiopathic arthritis in Alsace, France. J Rheumatol. 2006;33:1377–81.
3. Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group. N Engl J Med. 1992;326:1043–9. doi:10.1056/NEJM199204163261002.
4. Dueckers G, Guillaud N, Arboagat M, Dannecker G, Foeldvari I, Frosch M, et al. Evidence and consensus based treatment guidelines 2010 for juvenile idiopathic arthritis by the German Society of Paediatric Rheumatology. Klin Padiatr. 2011;223:386–94. doi:10.5555/kp.2010.0013-1287837.
5. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RJ, DeWitt EM, et al. American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63:465–82. doi:10.1002/arcc.20460.
6. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis. 2009;68:635–41. doi:10.1136/ard.2003.014886.
7. Horneff G, Smehling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63:1638–44. doi:10.1136/ard.2003.014868.
8. Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:9810–20. doi:10.1056/NEJMoa0706290.
9. Horneff G, Foeldvari I, Minden K, Moebius D, Hospach T. Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatology (Oxford). 2011;50:230–6.
10. Horneff G, Klein A, Oommen PT, Hospach A, Foeldvari I, Feddersen I, Minden K. Update on malignancies in children with juvenile idiopathic arthritis in the German BIKER Registry.Clin Exp Rheumatol. 2016 Sep 8. [Epub ahead of print].
11. Romano M, Pontikaki I, Gattinara M, Ardoino I, Donati C, Boracchi P, et al. Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients. Rheumatol. 2013;51:278–85. doi:10.4081/rheumatol.2013.668.
12. Davies R, Southwood TR, Kearsley-Fleet L, Lunt M, Hyrich KL, British Society for Paediatric, Adolescent Rheumatology Etanercept Cohort Study. Medically significant infections are increased in patients with juvenile idiopathic arthritis treated with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatol. 2015;62:1349–58. doi:10.1136/annrheumdis-2014-205351.
13. Barthel D, Ganser G, Kuester RM, Orkien N, Minden K, Girschick HJ, et al. Inflammatory bowel disease in juvenile idiopathic arthritis patients treated with biologics. J Rheumatol. 2015;42:2160–5. doi:10.3899/jrheum.140472.
14. Sandborn WJ, Hanauer SB, Katz S, Saffi M, Wolf DG, Baerg RD, et al. Etanercept for active Crohn’s disease: a randomised, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088–94.
15. Foeldvari I, Becker I, Hornell G. Uveitis events during Adalimumab, Etanercept, and methotrexate therapy in juvenile idiopathic arthritis: data from the biologics in Pediatric Rheumatology Registry. Arthritis Care Res (Hoboken). 2015;67:1529–35.
16. Anink J, Otten MH, Gorter SL, Prince FHM, van Rossum MAJ, van den Berg JM, et al. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab? Rheumatology (Oxford). 2013;52:1674–9. doi:10.1093/rheumatology/ket170.
17. Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, Maling M, et al. Early aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis. 2011;70:1605–12. doi:10.1136/annrheumdis-2010-201347.